The global anti-infectives market size reached US$ 130.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 157.6 Billion by 2028, exhibiting a growth rate (CAGR) of 3.46% during 2023-2028.
Anti-infectives are medicines that act against infections, either by inhibiting the spread or killing the infectious agent outright. These medicines include antibiotics, antivirals, antifungals, antimalarials, anthelmintics, and antiprotozoals. They are generally administered through oral, parenteral, and topical routes. They are widely used to treat minor infectious diseases, including pneumonia and tuberculosis. Apart from this, anti-infectives are also utilized during routine procedures and surgeries, such as cesarian section and joint replacement, which are associated with a high risk of severe infection.
Anti-infectives Market Trends:
- The global anti-infectives market is primarily driven by rising incidences of infectious diseases across the globe. Anti-Infinitives are used to treat infections, including viruses, bacteria, parasites, and fungi. Additionally, the development of novel drugs that are formulated using different strategies, such as natural products, quorum sensing inhibitors, biofilm disruptors, gallium-based drugs, cyclodextrin inhibitors, and light-based antimicrobials, are providing an impetus to the market growth. In line with this, the latest innovations in drug discovery procedures, such as stem cells and organ-on-chip (OOC) technologies, to enhance drug trial processes are creating a positive outlook for the market. Furthermore, the increasing product adoption due to the advent of the COVID-19 disease and induced infections, such as aspergillosis, invasive candidiasis, and mucormycosis, is strengthening the growth of the market. Besides this, the increasing number of new anti-infective drugs being approved by the regulatory authorities is acting as another growth-inducing factor. Moreover, the implementation of favorable government policies, rising investments in developing new and innovative drugs, increasing awareness among individuals about infectious diseases, and rapidly improving healthcare infrastructure are anticipated to impel the growth of the market in the coming years.
Key Market Segmentation:
- IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-infectives market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, route of administration and distribution channel.
Breakup by Type:
Breakup by Route of Administration:
- Intravenous (IV)
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Speciality Pharmacies
- Online Stores
Breakup by Region:
- North America
- United States
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
- The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Cipla Health Ltd. (Cipla Limited), F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Lupin Limited, Sandoz AG (Novartis AG) and Sun Pharmaceutical Industries Limited.
Key Questions Answered in This Report:
- How has the global anti-infectives market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global anti-infectives market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global anti-infectives market and who are the key players?
- What is the degree of competition in the industry?